SG11201704764PA - Inhibitors of cellular necrosis and related methods - Google Patents

Inhibitors of cellular necrosis and related methods

Info

Publication number
SG11201704764PA
SG11201704764PA SG11201704764PA SG11201704764PA SG11201704764PA SG 11201704764P A SG11201704764P A SG 11201704764PA SG 11201704764P A SG11201704764P A SG 11201704764PA SG 11201704764P A SG11201704764P A SG 11201704764PA SG 11201704764P A SG11201704764P A SG 11201704764PA
Authority
SG
Singapore
Prior art keywords
inhibitors
related methods
cellular necrosis
necrosis
cellular
Prior art date
Application number
SG11201704764PA
Inventor
Junying Yuan
Yijun Zhou
Shan Qian
Dawei Ma
Original Assignee
Harvard College
Shanghai Inst Organic Chemistry Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Shanghai Inst Organic Chemistry Cas filed Critical Harvard College
Publication of SG11201704764PA publication Critical patent/SG11201704764PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201704764PA 2014-12-11 2015-12-11 Inhibitors of cellular necrosis and related methods SG11201704764PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410764426 2014-12-11
CN201410767595 2014-12-11
US201562105475P 2015-01-20 2015-01-20
US201562105462P 2015-01-20 2015-01-20
PCT/US2015/065349 WO2016094846A1 (en) 2014-12-11 2015-12-11 Inhibitors of cellular necrosis and related methods

Publications (1)

Publication Number Publication Date
SG11201704764PA true SG11201704764PA (en) 2017-07-28

Family

ID=56108283

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704764PA SG11201704764PA (en) 2014-12-11 2015-12-11 Inhibitors of cellular necrosis and related methods

Country Status (14)

Country Link
US (3) US9944628B2 (en)
EP (1) EP3229807A4 (en)
JP (1) JP2017538712A (en)
KR (1) KR20170123607A (en)
CN (1) CN107530350A (en)
AR (1) AR102981A1 (en)
AU (1) AU2015360291A1 (en)
CA (1) CA2970525A1 (en)
EA (1) EA201791289A1 (en)
IL (1) IL252827A0 (en)
MX (1) MX2017007607A (en)
SG (1) SG11201704764PA (en)
TW (1) TW201632516A (en)
WO (1) WO2016094846A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513481A (en) 2008-12-23 2012-06-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ Small molecule inhibitors of necrotosis
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
EP3229807A4 (en) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibitors of cellular necrosis and related methods
CN106619619A (en) * 2017-01-06 2017-05-10 浙江大学 Application of compound HUBIN-1 in preparation of drug for preventing and/or treating liver inflammatory diseases
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN110914275A (en) * 2017-05-17 2020-03-24 戴纳立制药公司 Compounds, compositions and methods
CN108191835A (en) * 2018-01-09 2018-06-22 中国药科大学 It is a kind of novel to contain pyrrole ring and indoline structure RIP1 kinase inhibitors and application thereof
CN110759895B (en) * 2018-07-25 2020-10-27 浙江大学 Novel RIP1/RIP3 dual-target inhibitor and application thereof in treatment of multi-target disease with one drug
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
US20210147842A1 (en) * 2019-11-13 2021-05-20 President And Fellows Of Harvard College Methods and compositions for inhibiting necroptosis in neurovascular and/or neurodegenerative diseases or disorders
CN112263576A (en) * 2020-09-30 2021-01-26 浙江大学 Application of compound ZJU-37 in preparation of drugs for preventing and/or treating liver diseases

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1044508A (en) * 1911-04-21 1912-11-19 Ajax Forge Company Railway-frog.
BE789948A (en) 1971-10-13 1973-04-11 Sandoz Sa NEW DERIVATIVES OF PYRAZOLE, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
JPS5113156B2 (en) 1972-10-21 1976-04-26
US4016037A (en) 1975-10-15 1977-04-05 Ajinomoto Co., Inc. Method for producing L-amino acid
US4110536A (en) 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
DE2728523C2 (en) 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazole-5-carboxylic acid (cyclohexylmethyl) amide, agents having a herbicidal and growth-regulating action, containing this compound and a process for its preparation
JPS55136279A (en) 1979-04-09 1980-10-23 Ajinomoto Co Inc Preparation of tryptophan hydantoin
JPS5810074B2 (en) 1979-07-18 1983-02-24 味の素株式会社 new microorganisms
US4332952A (en) 1980-07-28 1982-06-01 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
SG56656G (en) 1980-07-28 1987-03-27 Pfizer Hypoglycemic 5-substituted oxazolidine-2, 4-diones
DE3567460D1 (en) 1984-06-07 1989-02-16 Pfizer Ltd Dihydropyridines
JPS6122081A (en) 1984-07-10 1986-01-30 Mitsui Toatsu Chem Inc Preparation of hydantoin compound
US4684735A (en) 1985-07-01 1987-08-04 Stauffer Chemical Company Promotion of raney nickel hydrogenation catalyst
JPH0623148B2 (en) 1985-09-05 1994-03-30 三井東圧化学株式会社 Method for producing N-acetyl-DL-amino acid
CA1292840C (en) 1985-09-26 1991-12-03 David Harry Hawke Sequencing of peptides
JPH0659227B2 (en) 1985-11-08 1994-08-10 三井東圧化学株式会社 Method for producing D-α-amino acid
JPS6225990A (en) 1986-07-19 1987-02-03 Kanegafuchi Chem Ind Co Ltd Production of d-alpha-amino acid
US4705864A (en) 1986-11-10 1987-11-10 The Standard Oil Company Aryl oxime derivatives of hydantoins
US4911931A (en) 1987-08-03 1990-03-27 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
JP2661111B2 (en) 1988-03-09 1997-10-08 三菱化学株式会社 Method for producing DN-carbamyl-α-amino acid
US4868061A (en) 1988-05-19 1989-09-19 The Standard Oil Company Olefinic aryl oxime derivatives of hydantoins
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
JPH0219363A (en) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd Imidazolidine derivative
WO1990004183A1 (en) 1988-10-07 1990-04-19 Commonwealth Scientific And Industrial Research Organisation Method for preparation of thiohydantoins and for protein sequence analysis
DE58905691D1 (en) 1989-01-02 1993-10-28 Ruetgerswerke Ag Process for the production of L-alpha amino acids.
JPH054910A (en) 1990-07-31 1993-01-14 Nikka Chem Co Ltd Cosmetic composition
CA2088195A1 (en) 1990-08-31 1992-03-01 David C. Horwell Cholecystokinin antagonists, their preparation and therapeutic use
JP2651755B2 (en) 1991-03-01 1997-09-10 富士写真フイルム株式会社 Silver halide color photographic materials
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5693643A (en) 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
DE69223573D1 (en) 1991-09-16 1998-01-29 Merck & Co Inc Hydantoin and succinimide substituted spiroindanylcamphorsulfonyl as oxytocin antagonists
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JP3163361B2 (en) 1992-03-12 2001-05-08 味の素株式会社 Method for producing 5-alkylhydantoin derivative
US5574030A (en) 1992-07-14 1996-11-12 Nippon Chemiphar Co., Ltd. N-aminoalkyl-substituted nitrogen-containing five membered heterocyclic compounds
PH31474A (en) 1992-07-14 1998-11-03 Nippon Chemiphar Co N-aminoboalkyl-substituted nitrogen-containing five membered heterocyclic compounds.
US5830854A (en) 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5338859A (en) 1993-02-12 1994-08-16 Hoechst Celanese Corporation Process for the production of calcium salts of hydantoic acids
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
DE69513832T2 (en) 1994-09-08 2000-04-13 Lilly Co Eli EXCITATIVE AMINO ACID RECEPTOR ANTAGONISTS
AU4424496A (en) 1995-03-27 1996-10-16 Warner-Lambert Company A method for the synthesis of mixtures of compounds
US6166054A (en) 1995-03-31 2000-12-26 Nihon Nohyaku Co., Ltd. Agricultural and horticultural disease controller and a method for controlling the diseases
US5674734A (en) 1995-05-18 1997-10-07 President And Fellows Of Harvard College Cell death protein
DE19519717C1 (en) 1995-05-30 1996-08-22 Degussa New microorganism DSM 9771 for prepn of L-alpha-amino acids
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US5962478A (en) 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
AU7457796A (en) 1995-10-23 1997-05-15 Tularik Inc. Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays
EP0907643B1 (en) 1996-04-24 2003-01-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP0930305B1 (en) 1996-09-30 2003-05-14 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
US5859190A (en) 1997-02-04 1999-01-12 Trega Biosciences, Inc. Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein
EP0966447B1 (en) 1997-03-03 2003-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Small molecules useful in the treatment of inflammatory disease
IL126024A0 (en) 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
DE69907331T2 (en) 1998-07-30 2003-10-23 Nihon Nohyaku Co Ltd Fungicidal composition containing a 1,2,3-thiadiazole derivative and their use
DE59905623D1 (en) 1998-09-22 2003-06-26 Degussa Process for the preparation of imidazolidine-2,4-diones
US6020198A (en) 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
WO2001007048A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007044A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6756394B1 (en) 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
WO2001028493A2 (en) 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
WO2001074807A1 (en) 2000-03-30 2001-10-11 Sagami Chemical Research Center Indolylpyrrole derivatives and cell death inhibitors
US20020155172A1 (en) 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
GB0011071D0 (en) 2000-05-08 2000-06-28 Novartis Ag Organic compounds
US6846643B2 (en) 2000-08-14 2005-01-25 Boehringer Ingelheim Pharmaceuticals, Inc. Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy
US20020064736A1 (en) 2000-09-27 2002-05-30 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye
JP2002145192A (en) 2000-11-07 2002-05-22 Yamaha Motor Co Ltd Fuel tank structure for surface vehicle
JP4529338B2 (en) 2001-03-08 2010-08-25 味の素株式会社 DNA encoding hydantoinase, DNA encoding N-carbamyl-L-amino acid hydrolase, recombinant DNA, transformed cell, protein production method and optically active amino acid production method
HUP0401492A3 (en) 2001-09-14 2008-05-28 Novo Nordisk As Novel ligands for the hisb10 zn2+ sites of r-state insulin hexa
AU2002363655A1 (en) 2001-11-14 2003-05-26 Novartis Ag Non-peptide somatostatin receptor ligands
JPWO2003043988A1 (en) 2001-11-22 2005-03-10 小野薬品工業株式会社 Piperidin-2-one derivative compound and drug containing the compound as an active ingredient
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
JP3659224B2 (en) 2001-12-26 2005-06-15 村田機械株式会社 Internet facsimile machine
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
WO2003068914A2 (en) 2002-02-11 2003-08-21 Wyeth Solution structure of rip dd and uses therof
WO2004023146A2 (en) 2002-09-06 2004-03-18 Mount Sinai Hospital Methods for assaying protein-protein interactions
WO2004050894A2 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
WO2004056347A2 (en) 2002-12-20 2004-07-08 Novo Nordisk A/S Pharmaceutical compositions comprising insulin and legends of insulin hexamer
FR2850652B1 (en) 2003-01-31 2008-05-30 Aventis Pharma Sa NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
EP1610812A1 (en) 2003-03-11 2006-01-04 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
EP1605967A1 (en) 2003-03-13 2005-12-21 Novo Nordisk A/S Novel nph insulin preparations
SI2384753T1 (en) * 2003-08-29 2016-06-30 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
JP4452914B2 (en) 2003-09-08 2010-04-21 味の素株式会社 Novel transporter protein
DE10342839A1 (en) 2003-09-17 2005-04-28 Symrise Gmbh & Co Kg Use of hydantoin derivatives for cosmetic, dermatological or therapeutic lightening of the skin and hair, act by inhibiting tyrosinase or other processes involved in pigmentation
US20080019909A1 (en) 2003-09-17 2008-01-24 Francis Ka-Ming Chan Modulation of Programmed Necrosis
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US8097629B2 (en) 2004-02-19 2012-01-17 Bayer Pharma Aktiengesellschaft Dihydropyridinone derivatives
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
GB0410379D0 (en) 2004-05-11 2004-06-16 Univ Leicester Treatment of cancer
KR101155288B1 (en) 2004-07-30 2012-07-02 엑셀리시스, 인코포레이티드 Pyrrole Derivatives as Pharmaceutical Agents
US7595337B2 (en) 2005-02-10 2009-09-29 Merck & Co. Inc. Mitotic kinesin inhibitors
WO2006103995A1 (en) 2005-03-25 2006-10-05 Kaneka Corporation PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE α-AMINO ACID DERIVATIVE
BRPI0615307A2 (en) 2005-08-25 2009-08-04 Schering Corp alpha2c adrenoreceptor agonists
BRPI0617271A2 (en) 2005-10-11 2011-07-19 Intermune Inc viral replication inhibitors
CA2628259A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
EP1968583A4 (en) 2005-12-20 2010-09-15 Harvard College Compounds, screens, and methods of treatment
AR056882A1 (en) 2006-02-01 2007-10-31 Bayer Cropscience Sa DERIVATIVES OF THE FUNGICIDE N- CICLOALQUIL- BENCIL- AMIDA
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
EP2041141A2 (en) 2006-07-13 2009-04-01 4Sc Ag Benzopyranopyrazoles
EP2076134A4 (en) 2006-10-10 2020-07-29 President and Fellows of Harvard College Compounds, screens, and methods of treatment
ATE551328T1 (en) 2007-06-06 2012-04-15 Dsm Sinochem Pharm Nl Bv NOVEL 5-SUBSTITUTED HYDANTOINS
EP3034494A1 (en) 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
JP2011517313A (en) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． Metalloenzyme inhibitors that use a metal binding moiety in combination with a targeting moiety
EP2245182A1 (en) 2008-02-14 2010-11-03 F. Hoffmann-La Roche AG Prediction of bone marrow toxicity
US20120061324A1 (en) * 2008-03-28 2012-03-15 Global Material Technologies, Inc. Element removal process and apparatus
US8304421B2 (en) 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
JP2012513481A (en) 2008-12-23 2012-06-14 プレジデント アンド フェロウズ オブ ハーバード カレッジ Small molecule inhibitors of necrotosis
JP2010202575A (en) 2009-03-03 2010-09-16 Takeda Chem Ind Ltd Heterocyclic compound
DE102009002044A1 (en) 2009-03-31 2010-10-07 Evonik Degussa Gmbh Dipeptides as feed additives
JP5332882B2 (en) 2009-04-30 2013-11-06 豊田合成株式会社 Semiconductor light emitting device
JP2010275229A (en) 2009-05-28 2010-12-09 Ikutoku Gakuen Hydantoin derivative
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
AR080234A1 (en) 2010-02-25 2012-03-21 Marrone Bio Innovations Inc BACTERIAL CEPA ISOLATED FROM THE BURKHOLDERIA AND METABOLITES PESTICIDES OF THE SAME
KR20130006664A (en) 2010-03-16 2013-01-17 다나-파버 캔서 인스티튜트 인크. Indazole compounds and their uses
WO2011123609A1 (en) 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
JP2014509852A (en) 2011-03-07 2014-04-24 ジ・オハイオ・ステート・ユニバーシティ Mutagenic activity induced by microRNA-155 (miR-155) links inflammation and cancer
WO2012154858A1 (en) 2011-05-09 2012-11-15 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
CN102850252B (en) 2011-06-30 2014-08-13 山东大学 Preparation method for 3,5,5'-trisubstituted hydantoin
WO2013013826A1 (en) 2011-07-27 2013-01-31 Friedrich-Alexander-Universität Erlangen-Nürnberg Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract
US9314328B2 (en) 2011-08-16 2016-04-19 W. L. Gore & Associates, Inc. Branched stent graft device and deployment
AU2012301466B2 (en) 2011-08-27 2015-07-23 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus Burkholderia and pesticidal metabolites therefrom-formulations and uses
US20140357570A1 (en) * 2011-10-21 2014-12-04 Massachusetts Eye And Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2844764B1 (en) 2012-05-04 2016-06-22 Novartis AG Biomarkers for iap inhibitor therapy
EP2864362A4 (en) 2012-06-26 2015-11-18 Biovalence Sdn Bhd Anticancer treatment
US20150185215A1 (en) 2012-07-02 2015-07-02 Cell Assay Innovations, Inc. Cell-Based Assays For Post-Translational Enzyme Activity
JPWO2014126127A1 (en) 2013-02-13 2017-02-02 国立大学法人北海道大学 Pharmaceutical composition for treatment of necroptosis-related diseases and method for screening active ingredients thereof
TWI637951B (en) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 Heterocyclic amides as kinase inhibitors
WO2014134351A2 (en) 2013-02-27 2014-09-04 The Broad Institute, Inc. T cell balance gene expression, compositions of matters and methods of use thereof
WO2014152182A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Synthesis of hydantoin containing peptide products
US20160051629A1 (en) 2013-04-15 2016-02-25 Yeda Research And Development Co. Ltd. Inhibition of rip kinases for treating lysosomal storage diseases
GB201316651D0 (en) 2013-09-19 2013-11-06 Univ Southampton Asthma
WO2015039705A1 (en) 2013-09-23 2015-03-26 Carl Zeiss Smt Gmbh Multilayer mirror
EP2857839A1 (en) 2013-10-01 2015-04-08 AIT Austrian Institute of Technology GmbH Breast cancer diagnostic method and means
US20150147780A1 (en) 2013-11-22 2015-05-28 World Biotechnology LLC Method for harvesting organic compounds from genetically modified organisms
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US20150191511A1 (en) 2014-01-08 2015-07-09 World Biotechnology LLC Genetically Modified Organisms to Produce Organic Compounds
WO2015154197A1 (en) 2014-04-11 2015-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
US20170226514A1 (en) 2014-08-13 2017-08-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prevention of tumour metastasis by inhibition of necroptosis
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
WO2016044777A1 (en) 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
EP3017825A1 (en) 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same
EP3229807A4 (en) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibitors of cellular necrosis and related methods
JP6772141B2 (en) 2014-12-24 2020-10-21 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン Necrosis inhibitor
AU2015371824B2 (en) 2014-12-24 2019-09-19 National Institute Of Biological Sciences, Beijing Necrosis inhibitors

Also Published As

Publication number Publication date
AR102981A1 (en) 2017-04-05
CN107530350A (en) 2018-01-02
EA201791289A1 (en) 2017-12-29
US10508102B2 (en) 2019-12-17
US9499521B2 (en) 2016-11-22
US20160304498A1 (en) 2016-10-20
US9944628B2 (en) 2018-04-17
EP3229807A4 (en) 2018-10-17
US20160168128A1 (en) 2016-06-16
EP3229807A1 (en) 2017-10-18
AU2015360291A1 (en) 2017-07-13
IL252827A0 (en) 2017-08-31
MX2017007607A (en) 2018-05-28
WO2016094846A1 (en) 2016-06-16
CA2970525A1 (en) 2016-06-16
US20190023690A1 (en) 2019-01-24
KR20170123607A (en) 2017-11-08
JP2017538712A (en) 2017-12-28
TW201632516A (en) 2016-09-16

Similar Documents

Publication Publication Date Title
HK1259232A1 (en) Substituted inhibitors of menin-mll and methods of use
ZA201700241B (en) Mnk inhibitors and methods related thereto
IL252827A0 (en) Inhibitors of cellular necrosis and related methods
IL251584A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
HK1244792B (en) Necrosis inhibitors
IL246902A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
ZA201604272B (en) Inhibitors of glutaminase
IL267291B (en) Ectonucleotidase inhibitors and methods of use thereof
IL259801A (en) Inhibitors of ezh2 and methods of use thereof
HK1244480A1 (en) Necrosis inhibitors
IL257061A (en) Inhibitors of ezh2
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
EP3177327A4 (en) Inhibitors of myh7b and uses thereof
SG11201608761PA (en) Methods of cellular reprogramming
IL249086A0 (en) Nampt inhibitors and methods
PL3362450T3 (en) N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis